These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 9466331

  • 1. Changes in urinary excretions of C-telopeptide and cross-linked N-telopeptide of type I collagen during pregnancy and puerperium.
    Yamaga A, Taga M, Minaguchi H.
    Endocr J; 1997 Oct; 44(5):733-8. PubMed ID: 9466331
    [Abstract] [Full Text] [Related]

  • 2. The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorption.
    Taga M, Uemura T, Minaguchi H.
    J Endocrinol Invest; 1998 Mar; 21(3):154-9. PubMed ID: 9591210
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
    Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Bréart G, Meunier PJ, Delmas PD.
    J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N, Parés A, Alvarez L, Martínez de Osaba MJ, Monegal A, Peris P, Ballesta AM, Rodés J.
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [Abstract] [Full Text] [Related]

  • 10. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.
    Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L.
    Br J Haematol; 2003 Jan; 120(2):235-42. PubMed ID: 12542480
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover.
    Amama EA, Taga M, Minaguchi H.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):333-8. PubMed ID: 9467536
    [Abstract] [Full Text] [Related]

  • 13. Urinary excretion of cross-linked N-telopeptides of type 1 collagen to assess bone resorption in infants from birth to 1 year of age.
    Lapillonne A, Travers R, DiMaio M, Salle BL, Glorieux FH.
    Pediatrics; 2002 Jul; 110(1 Pt 1):105-9. PubMed ID: 12093954
    [Abstract] [Full Text] [Related]

  • 14. New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis.
    Guerrero R, Diaz Martin MA, Diaz Diego EM, Disla T, Rapado A, de la Piedra C.
    Osteoporos Int; 1996 Jul; 6(4):297-302. PubMed ID: 8883118
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis.
    Garnero P, Delmas PD.
    Bone; 2003 Jan; 32(1):20-6. PubMed ID: 12584032
    [Abstract] [Full Text] [Related]

  • 19. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes.
    Fassbender WJ, Gödde M, Brandenburg VM, Usadel KH, Stumpf UC.
    Adv Med Sci; 2009 Jan; 54(1):1-6. PubMed ID: 19482729
    [Abstract] [Full Text] [Related]

  • 20. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD.
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.